Argenx
ARGX
#523
Rank
C$57.81 B
Marketcap
$951.51
Share price
-1.58%
Change (1 day)
86.12%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Earnings for Argenx (ARGX)

Earnings in 2024 (TTM): -C$83.46 Million

According to Argenx 's latest financial reports the company's current earnings are C$1.85 Billion. In 2023 the company made an earning of -C$0.45 Billion, an increase over its 2022 earnings that were of -C$1.06 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Argenx from 2013 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -C$83.46 Million-81.13%
2023 -C$0.45 Billion-58.25%
2022 -C$1.06 Billion
2019 -C$0.29 Billion124.95%
2018 -C$0.13 Billion132.04%
2017 -C$55.4 Million54.86%
2016 -C$35.77 Million33%
2015 -C$26.9 Million13.63%
2014 -C$23.67 Million46.25%
2013 -C$16.19 Million